Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)

Launched by NANJING MEDICAL UNIVERSITY · Jan 6, 2021

Keywords

ClinConnect Summary

The PANDA III trial is studying whether statin medications, which are commonly used to lower cholesterol, can help protect patients from heart and organ problems after surgery for serious aortic conditions, such as aortic dissection or aneurysm. The researchers are interested in how statins might reduce inflammation in the body, which can lead to better recovery outcomes for patients who have had these types of surgeries.

To participate in this trial, you should be between 18 and 85 years old and have had surgery for an aortic issue but do not have high cholesterol. Other risk factors for heart disease, such as high blood pressure, diabetes, or being a smoker, may also make you eligible. Participants will be asked to sign consent to join the study, and while they will receive the treatment, they will also be closely monitored for any effects. It’s important to know that certain people, such as those with allergies to statins or specific liver conditions, cannot participate in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) Patients with aortic dissection/ulceration/intermural hematoma/aortic aneurysm who underwent aortic arch replacement or endoluminal isolation or hybrid therapy;
• • (2) Paitents without clinically significant hyperlipidemia but with cardiovascular disease risk factors (such as male ≥45 years old, female ≥55 years old, hypertension, diabetes, chronic kidney disease, obesity, low HDL cholesterol, smoking, alcohol consumption, family history of early onset ischemic cardiovascular disease) and no previous use of statins;
• • (3) Patients are between 18 and 85 years old, male or female;
• • (4) Agree to participate in the study and sign the informed consent.
• Exclusion Criteria:
• • (1) Patients with allergy to statins;
• • (2) patients with active liver disease;
• • (3) patients with myopathy;
• • (4) Lactating women and pregnant women;
• • (5) Patients with mental diseases, drug and alcohol dependence;
• • (6) Refuse to participate in the study or sign the informed consent.